MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WAYS, D. K.
Right arrow Articles by ONTJES, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WAYS, D. K.
Right arrow Articles by ONTJES, D. A.

Molecular Pharmacology, Vol 12, 789-799, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Inhibition of Adrenocorticotropin Effects on Adrenal Cell Membranes by Synthetic Adrenocorticotropin Analogues: Correlation of Binding and Adenylate Cyclase Activation

D. KIRK WAYS 1, CAROL F. ZIMMERMAN 1, and DAVID A. ONTJES 1

1 Departments of Pharmacology and Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

Human ACTH and a number of ACTH peptide fragments were prepared by solid-phase synthesis. Of the analogues tested, only ACTH1-39 and ACTH1-24 stimulated rat adrenal membrane adenylate cyclase in vitro. Several shorter fragments, including ACTH6-39, ACTH9-24, ACTH9-19 amide, ACTH9-20, ACTH9-18, and ACTH12-39, inhibited stimulation of the enzyme by native bovine ACTH. The inhibition produced by this group of peptides appears to be specific for ACTH-stimulated adrenal adenylate cyclase. Basal and fluoride-stimulated enzyme activity in adrenal and fluoride- or epinephrine-stimulated activity in liver were not inhibited by ACTH9-24. To elucidate further the action of the inhibitory peptides, we tested their ability to inhibit the binding of [125I]ACTH1-24 to adrenal particles. Peptides having either agonist or antagonist activity in the adenylate cyclase assay were effective competitors for binding. The order of potency according to both adenylate cyclase inhibition and competitive binding affinity was ACTH6-39 > ACTH9-19 amide cong ACTH9-24 > ACTH9-20 cong ACTH9-18 > ACTH12-39. The analogues ACTH1-8, ACTH9-16, and ACTH19-39 were inactive in both the adenylate cyclase and binding systems. Comparison of this series of closely related peptides in two independent assay systems should more clearly define the structural requirements for the binding of ACTH to its membrane receptor.

Submitted on November 24, 1975
Accepted on May 4, 1976







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics